IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Yang et al.

Serial No:

Not Yet Assigned

Filed:

Herewith

For: Cell Regulatory Genes, Encoded Products, and

Uses Related Thereto

Atty Docket No.: HMV-038.04

Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, postage prepaid, "Post Office to Addressee," in an envelope addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, an November 18, 2003

Express Mail Label No.: EV 327716676

Bv:

John Barretto

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97 (b)(3)

Sir:

Submitted herewith on Form PTO-1449 is a list of publications known to Applicants and/or their Attorney/Agent in compliance with the requirement of 37 C.F.R § § 1.56 and 1.97(c). Copies of some these publications were submitted in association with co-pending related application U.S.S.N.: 09/174,493, filed on October 15, 1998 and therefore are not required to be provided in this application. In particular, references cited herein as AA-AK were submitted as references AA-AK in the IDS filed on July 15, 1999 and references cited herein as AL-BO were submitted as references AA-BD in the IDS filed on September 12, 2002. Copies of publications (BP-BS) are provided herewith.

Applicants have cited for the Examiner's consideration certain issued U.S. patents and copending U.S. patent applications that are owned at least in part by the assignee of this application, that describe subject matter related to the present invention. The co-pending applications are listed herewith in accordance with M.P.E.P. 609 III.D which states: "Applicants may wish to list U. S. patent application numbers on other than Form PTO-1449 or PTO/SB/08A and 08B format to avoid the application numbers of pending applications being published on the patent. If a citation is not printed on the patent but has been considered by the examiner in accordance with this section, the patented file will reflect that fact as noted in subsection III.C(2) above."

No copies of the co-pending applications have been provided. If the Examiner wishes to have copies of the co-pending applications, Examiner should contact the Attorney of record. Applicants respectfully request that the Examiner consider these listed documents and indicate that each was considered by making appropriate notations on this Information Disclosure Statement.

Examiner Initials	Our docket no.	S.N.	Title	Filing Date	Status	Document Enclosed	
	HMV-038.01	09/174,493	Cell Regulatory Genes, Encoded Products, and Uses Related Thereto	October 15, 1998	Pending	No.	
	HMV-038.02	09/538,106	Cell Regulatory Genes, Encoded Products, and Uses Related Thereto	March 29, 2000	Pending	No.	
	HMV-038.03	09/529,583	Cell Regulatory Genes, Encoded Products, and Uses Related Thereto	October 15, 1998	Pending	No.	
Date Consid	lered:		Examiner	's Name:			

Applicants have listed dates of publication on the attached Form PTO-1449 for the cited documents based on information presently available to the undersigned. However, the listed publication dates should not be construed that the information in the cited documents was actually published or otherwise publicly available on the date indicated.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached Form PTO-1449.

20/569607.1 - 2 -

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that each or all of the listed documents are material or constitute "prior art." Further, if the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Moreover, the Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Although we believe that we have provided for the fee due in connection with this submission, the Commissioner is authorized to credit any overpayment or charge any deficiencies to/from our **Deposit Order Account No. 06-1448**.

Should there be any questions after reviewing this paper, the Examiner is invited to contact the undersigned at (617) 832-1000.

Respectfully submitted,

s Walnes

FOLEY HOAG LLP

By: <u>(</u>

Jennifer K. Holmes

Reg. No. 46,778 Agent for Applicants

Dated: November 18, 2003

Customer No.: 25181

Patent Group Foley Hoag LLP 155 Seaport Boulevard Boston, MA 02210-2600

Telephone: (617) 832-1000 Facsimile: (617) 832-7000

20/569607.1 - 3 -

orm PTO-1449 INFORMATION DISCLOSURE CITATION				Docket Number (Optional) Application Number					Sheet Pa	-50 i Oi	
				HMV-038.04 Not Yet Assigned							
IN AN APPLICATION (Use several sheets if necessary)					cant et al.						
(Ose several sneed y necessary)				Filing Herev			Group Art Unit Not Yet Assigned				
-					S. PATENT DOCUMENTS	l			***		
EXAMINER									FILING D	G DATE	
INITIAL	DO	CUMENT NUMBER	DATE		NAME	CLAS	SS	SUBCLASS	IF APPROPRIAT		
						134 Y					
· ·	<u> </u>	I]	FORI	EIGN PATENT DOCUMEN	NTS			<u>. </u>		
	DOC	CUMENT NUMBER	DA'	TE	COUNTRY	CLAS	ss s	SUBCLASS	Translat YES	ion NO	
<u> </u>	1 1	WO 97/28186	08/07/97		PCT (English Abstract)				I LS	1 NO	
	AA	WO 97/28180	06/07		FCT (English Abstract)					\bot	
	AB	WO 99/19357	04/22	2/99	PCT						
									,		
		OTHE	S DO	CUM	ENTS	(Including	Author T	itle Date Per	l tinent Pages Et	(c.)	
	l	Kaghad, M. et al., "Mono	allelic	caly Exp	pressed Gene Related to p53 at 1p36,						
	AC	Human Cancers", Cell, V	'ol. 90	: 809-8	19 (Aug 22, 1997).						
		Killary et al "Definition	n of a t	tumor s	uppressor locus within human chromo	sone 3n21-n22	" Proc N	lati Acad Sci	USA Vol 89) nn	
	AD	1087-10881 (Nov. 1992)	. 01	iumor 5	appressor rocus within numeri ordenic	osono sper pee	,1100.11	71cuu. 5c.	. 0011, 101.03	,, pp	
	AE	Oren, "Lonely no more: I	P53 fir	nds it ki	n in a tumor suppressor haven", Cell	Vol. 90:829-83	2, Septemb	per 1997.			
	AE										
		Shaw, H. Phillip., "The R	ole of	fp53 in	Cell Cycle Regulation", Path. Res. Pi	ract. <u>192</u> : 669-6	75 (1996)				
	AF										
		Schmale, H. and Bamber	ger, C.	., "A no	ovel protein with strong homology to t	the tumor suppr	essor p53'	', Oncogene,	15: 1363-1367	7,	
	AG	(1997)				••	•				
		G. D. 1 "F.	62 D	takin N	(D) T C	· V 1 277	1.1605.16	06 (12 6	-1 1007)		
	AH	Steven Dickman, "First p	33 Ke	lative N	May Be a New Tumor Suppressor", Sc	rience, Vol. 277	: 1003-100	uo (12 Septen	nber 1997).		

		Wang, T., and Wang ¹ , H	., "p53	3, Appo	ptosis and Human Cancers", J. Form	os Med. Assoc.	Vol. 95, N	No. 7 (1996).			
	AI										
		Wylie Andrew., "Clues in	the p	53 mur	der mystery", Nature Vol. 389: 237-2	38 (18 Septemb	per 1997).				
	AJ										
		Vong et al. "m42 a m52"	Uome!	log et ?	q27-29, Encodes Multiple Products w	ith Transaction	ting Dacet	h Indusins	d Dominant		
	AK				q27-29, Encodes Multiple Products w Vol. 2:1-20 (September 1998).	nui Transactiva	ung, Deati	n-moucing an	d Dominant-		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

DATE CONSIDERED

EXAMINER

Sheet Page 2 of 5 Form PTO-1449 Docket Number (Optional) Application Number HMV-038.04 INFORMATION DISCLOSURE CITATION Not Yet Assigned Applicant IN AN APPLICATION Yang et al. (Use several sheets if necessary) Filing Date Group Art Unit Not Yet Assigned U.S. PATENT DOCUMENTS **EXAMINER** FILING DATE DOCUMENT NUMBER DATE INITIAL NAME CLASS **SUBCLASS** IF APPROPRIATE FOREIGN PATENT DOCUMENTS Translation DOCUMENT NUMBER DATE COUNTRY CLASS **SUBCLASS** YES NO WO 94/08241 ΑL April 14, 1994 **PCT** AM FR 2 692 594 23 Dec 1993 France WO 94/01563 AN 20 Jan 1994 **PCT** ΑO EP 377295 11 July 1990 Europe OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages Etc.) Arai et al., "Immunologically Distinct p53 Molecules Generated by Alternative Splicing" Mol. Cell. Biol. 6(9): 3232-3239 (September 1986). ΑP Bargonetti, J. et al., "Site-Specific Binding of Wild-Type p53 to Cellular DNA is Inhibited by SV40 T Antigen and Mutant p53", Genes Dev 6(10): 1886-1898 (October 1992). AQ Bodrug, "Molecular Analysis of a Constitutional X-Autosome Translocation in a Female with Muscular Dystrophy", Science 237: 1620-1624 (6 April 1993). AR De Fromentel et al., "Rainbow Trout p53: cDNA Cloning and Biochemical Characterization", Gene 112: 241-245 AS (1992).Desquiedt et al., "Nucleotide Sequence of Bovine p53 Tumor-Suppressor cDNA", DNA Seq. 5(4): 261-264 (1995). AT El-Deiry, WS et al., "Definition of a Consensus Binding Site for p53", Nat Genet 1(1): 45-49 (April 1992). ΑU Gryaznov et al., "Selective O-Phosphitilation With Nucleoside Phosphoramidite Reagents," Nucleic Acids Research, 20(8):1879-1882 (1992). AVHall, P. et al., "Expression of the p53 Homologue p63α and ΔNp63α in Normal and Neoplastic Cells" Carcinogenesis, 21(2):153-160 (Feb. 2000). ΑW EXAMINER DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to the applicant.

Sheet Page 3 of 5 Form PTO-1449 Docket Number (Optional) Application Number Not Yet Assigned HMV-038.04 INFORMATION DISCLOSURE CITATION Applicant IN AN APPLICATION Yang et al. (Use several sheets if necessary) Filing Date Group Art Unit Herewith Not Yet Assigned U.S. PATENT DOCUMENTS **EXAMINER** FILING DATE DOCUMENT NUMBER DATE NAME CLASS **SUBCLASS** IF APPROPRIATE INITIAL FOREIGN PATENT DOCUMENTS Translation DOCUMENT NUMBER DATE COUNTRY **CLASS SUBCLASS** YES OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages Etc.) Iwase et al., "Identification of Protein-Tyrosine Kinase Genes Preferentially Expressed in Embryo Stomach and Gastric Cancer," Biochemical & Biophysical. Research. Communications., 194(2):698-705 (July 1993). ΑX Kraegel et al., "Sequence Analysis of Canine p53 in the Region of Exons 3-8" Cancer Letters 92(2): 181-186 (June 8, 1995). ΑY Kunz, Jeannette et al., "Target of Rapamycin in Yeast, TOR2, Is and Essential Phosphatidylinositol Kinase Homolog Required for G1 Progession", Cell 73: 585-596 (May 7, 1993). ΑZ McNaughton et al., "A Cluster of Transposon-Like Repetitive Sequences in Intron 7 of the Human Dystrophin Gene" J. Mol. Biol, 232(1):314-321 (1993). BA Neumann et al., "Multifactorial Inheritance of Neural Tube Defects: Localization of the Major Gene and Recognition of Modifiers in ct Mutant Mice," Nature Genetics, 6(4):357-362 (April 1994). BB Oren, M. "Relationship of p53 to the Control of Apoptotic Cell Death", Semin Cancer Biol 5(3): 221-227 (June 1994). BC Parsa, R. et al., "Association of p63 Proliferative Potential in Normal and Neoplastic Human Keratinocytes" J. Invest Dermatol, 113:1099-1105 (Dec. 1999). Righi, E. et al., "Does p53 Immunostaining Improve Accuracy in Urine Cytology?" Diagnostic Cytopathology, 17(6):436-439 (Dec. 1997). BE Shaw, H. Phillip., "The Role of p53 in Cell Cycle Regulation," Path. Res. Pract. 192: 669-675 (1996). BF

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Strano, Sabrina et al., "From p53 to p53 Across p73", FEBS Letters 490: 163-170 (2001).

DATE CONSIDERED

EXAMINER

BG

		DISCLOSURE CITATION	HMV-038.04	ber (Optional)		Sheet Page 4 (Application Number Not Yet Assigned			
		APPLICATION ral sheets if necessary)	Applicant Yang et al.						
, 0.	36 36 767	ui sneets if necessary)	Filing Date			p Art Unit	 · · · · · - <u></u> -		
			Herewith IIS P	ATENT DOCUMENT		Yet Assigned			
EXAMINER				U.S. PATENT DOCUMENTS FILING DA					
INITIAL	DO	CUMENT NUMBER I	DATE	NAME	CLASS	SUBCLASS	IF APPROPRIA		
		1111	1		7/8		MI =		
		<u> </u>	FOREIGN	N PATENT DOCUME	NTS				
	DO	CUMENT NUMBER I	DATE	COUNTRY	CLASS	SUBCLASS	Translation		
							YES		
				· · · · · · · · · · · · · · · · · · ·					
			OCUMENT			or, Title, Date, Per			
	вн	Sturzbecher, HW et al., "Mutant p53 Proteins Bind hsp 72/73 Cellular Heat Shock-Related Proteins in SV40-Transformed Monkey Cells", Oncogene 1(2): 201-211 (May 1987).							
	BI	Teoule et al., "Gamma-Irradiation of Homodeoxyoligonucleotides ³² P-Labelled at One End: Computer Smulation of the Chain Length Distribution of the Radioactive Fragments," <i>Int. J. Radiat. Biol. Relat. Stud. Phys., Chem. Med.</i> , 51(3):429-439 (1987).							
	ВЈ	Wang, T. et al., "p53, Apoptosis and Human Cancers," J. Formos Med. Assoc., 95(7):509-522 (1996).							
	ВК	Wilson et al., "2.2. Mb of Contigious Nucleotide Sequence from Chromosome III of C. Elegans", <i>Nature</i> , 368: 38 (1994).							
	BL	Yang et al., "p63, a p53 Homolog at 3q27-29, Encodes Multiple Products with Transactivating, Death-Induce Dominant-Negative Activities," <i>Molecular Cell</i> 2: 1-20 (September 1998).							
	ВМ	Yang et al., "P63 and P73: P53 Mimics, Menaces and More", Nat Rev Mol Cell Biol 1(3): 199-207 (Dec.							
	BN	Yang et al., "p63 Is Essential for Regenerative Proliferation In Limb, Craniofacial and Epithelial Developmen Nature, Vol. 398:714-178 (Apr. 1999).							
	ВО	Sequence alignments cite	ed in co-pendi	ing application.			. .		
	ВР	Burgess et al., "Possible Dissociation of Heparin-binding and Mitogenic Activities of Heparin (Acidic Fibroblast Growth Factor-1 from Its Receptor-binding Activities by Site-Directed Mutagenesis of a Single Lysine Residue"							
	BQ	Lazar et al., "Transformi Biological Activities,	ng Grown Fac	ng Grown Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different					
AMINER				DATE CO	NSIDERED				

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Docket Number (Optional) HMV-038.04 Applicant			Application Number Not Yet Assigned						
		al sheets if necessary)		Yang et al. Filing Date Herewith				Group Art Unit Not Yet Assigned				
					PATENT DOCUM	ENTS	1.00.1	ot / tab/gited				
EXAMINER INITIAL	DOCUMENT NUMBER DA			TE	NAME	CLA	ASS	SUBCLASS	FILING DATE IF APPROPRIATE			
				FOREIG	N PATENT DOCU	IMENTS						
			-					1	Transla	tion		
	DO	CUMENT NUMBER	DA	TE	COUNTRY	CLA	ASS	SUBCLASS	YES	NO		
		ОТИ	FD DO	CUMEN	TC	(In al. di		Tid. D B.		<u> </u>		
	BR				r Res Ann Meeting 19			r, Title, Date, Pert Only	inent Pages E	ic.)		
	BS	Li et al (Zhonghua	Zhongl	iu Zazhi 1	994; 16(3):172-176)-	Abstract Only		····				
									-			

								···				
								• •				
										-		
EXAMINER					DA	TE CONSIDERED						
EXAMINER: conformance an	Initial nd not	if citation considered, v considered. Include co	vhether o	or not citati is form with	on is in conformance with next communication to	h MPEP § 609; Drathe applicant.	aw line	through citation	if not in			